Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis.

NCT04573673 · tracked via the Priya Life Science France tracker

Sponsor

University Hospital, Lille

Phase

Not applicable

Started

2021-12-01

Last updated

2025-12-23

Condition(s) studied

Multiple SclerosisLower Urinary Tract Symptoms

Investigational drug(s) / intervention(s)

PTNS de verumPTNS placebo

PTNS de verum: The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. The amplitude (Volt) will be adjusted by the patient according to the feeling.

PTNS placebo: The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. A resistor will be incorporated in the device to block the passage of electric current

Study summary

The present trial is designed to assess the efficacy and safety of transcutaneous tibial neuro-stimulation (TTNS) in improving bladder emptying in multiple sclerosis (MS) patients.

Patients presenting with MS and performing clean intermittent self-catheterization (CISC) to empty the bladder in the context of voiding dysfunction, will be eligible.

Included patients will be randomly assigned to two distinct arms

* PTNS de verum : patients will be treated with transcutaneous tibial neuro-stimulation at a rate of one session of 30 consecutive minutes daily for a period of 12 weeks.
* PTNS placebo : Patients will be treated with placebo (i.e. no current) transcutaneous tibial neuro-stimulation for 30 consecutive minutes daily for a period of 12 weeks (same treatment regimen as the experimental group).

Efficacy in improving voiding dysfunction will be assessed 12 weeks after randomization using the BVE ratio (Bladder Voiding Efficiency) = Ratio of urine volume / total bladder volume.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: * Patient with a diagnosis of multiple sclerosis * Patient with bladder-sphincter dyssinergia * Patient using clean intermittent self-catheterization as exclusive bladder management * Patient who has given written consent * Socially insured patient * Patient willing to comply with all study procedures and study duration Exclusion Criteria: * Patient with other associated neurological pathology * Patient with an Expanded Disability Status Scale (EDSS) score ≥ 6 * Patient with recurrent urinary tract infections (\> 3 episodes / year) * Patient with uncontrolled overactive bladder * Patient with uncontrolled detrusor hyperactivity * Patient with a bladder compliance disorder * Patient with tibial neuro-stimulation in the last 3 months * Patient treated with a sacral neuro-modulation * Patient who has received an intradermal injection of botulinum toxin A within the last 9 -months Patient who received alpha-blocker treatment within the last month Patient with benign prostatic hypertrophy (prostate volume \> 40 cc) - Last ultrasound scan \< 6 months. Patient with one or more bladder diverticulum(s) Patient with unilateral or bilateral renal Patient with unilateral or bilateral vesico-ureteral reflux Patient with impaired renal function (GFR according to CKD-EPI \< 60 ml/min/1.73m2) Patient with a metallic prosthesis on the lower limb Patient with a Pacemaker Pregnant patient

Primary outcome measure(s)

BVE ratio (Bladder Voiding Efficiency) = Ratio of urine volume / total bladder volume — At 12 weeks after randomization
BVE will be measured during the multi-channel urodynamic study

Trial sites (1)

Facility	City	Region	Status
Hop Claude Huriez Chu Lille	Lille	France	Recruiting

More University Hospital, Lille trials in France

Evaluation of Autonomic Nervous System Changes in Response to Stimulation by Sacral Neuromodulation Recruiting

Lung Disease and FLNA Mutations Starting soon

Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers Recruiting

Intact Cord Resuscitation in CDH Recruiting

Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome Recruiting

Other trials for the same condition

Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome Recruiting

EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis Recruiting

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis Active, not recruiting

The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. Recruiting

Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04573673 on ClinicalTrials.gov ↗ ← All trials in France